This morning, I have received copies of the FDA News on ESAs from the Pharmeacy Director, the Blood Bank Director, and the daily newsletters. Clearly people are concerned after the announcement on national news from the FDA that there are dangers associated with off-label usage of ESAs. Sadly, while blood conservation programs are big users or these products, it is often physicians not associated with such programs that are using the medications inappropriately, causing DUE's and investigations that validate the FDA's concerns. Perhaps this warning will get everyone on the same page and promote a better understanding of how these products can be used safely and cost-effectively.